News & Media
Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition 2024
Axcynsis Therapeutics won 2nd place in BCIC Annual Pitch Competition 2024 Singapore, May 3, 2024 - Axcynsis Therapeutics is proud and honoured to share that [...]
Axcynsis Therapeutics TO PRESENT AT BIOTECH SHOWCASE™ 2024
Axcynsis, Next Generation of ADC Singapore, December 26, 2023 – Axcynsis Therapeutics today announced that it is presenting at Biotech Showcase™ 2024. This year, registered [...]
Founder Dr Zou Bin Honoured with CEO of the Year
We are happy to share that our Founder and CEO, Dr Zou Bin, has won the APAC Insider 'Most Innovative Biotechnology Company CEO Singapore 2023' [...]
Axcynsis Therapeutics wins Best Antibody Conjugate Therapy Development Company 2023
We are honored and proud to receive the GHP Biotechnology Awards as the Best Antibody Conjugate Therapy Development Company in 2023. Thank you for [...]
WuXi AppTec BOLD: Spotlight I – The Next Wave of Cancer Therapeutics
Join our founder and CEO, Dr Zou Bin, together with nine other international biotech entrepreneurs to address unmet needs in oncology, and how these [...]
WuXi AppTec BOLD Program: Innovation That Matters
We are gearing up for the WuXi AppTec BOLD program: Innovation That Matters. On July 27-28, our Founder and CEO, Dr Zou Bin, will [...]
Business Times (21 June 2023): “Wanted: experts to sit on startups’ scientific advisory boards”
Published in Business Times 21 June 2023: "Wanted: experts to sit on startups' scientific advisory boards" ### About Axcynsis [...]
Axcynsis Therapeutics Appoints Professor Kyriacos Costa Nicolaou to its Scientific Advisory Board
May 02, 2023- Singapore Biotech Axcynsis Therapeutics Strengthens Scientific Team In Its Development Of Antibody Drug Conjugates for Cancer Therapeutics Axcynsis Therapeutics is thrilled [...]
Axcynsis Therapeutics Appoints Emeritus Professor Paul Herrling to its Scientific Advisory Board
Apr 04, 2023 - Singapore Biotech Axcynsis Therapeutics Strengthens Scientific Team In Its Development Of Antibody Drug Conjugate Cancer Therapeutics Axcynsis Therapeutics is proud [...]
Official opening of Axcynsis Therapeutics’ office and research facility in Shanghai China
Jan 06, 2023 – Singapore-based biotech start-up Axcynsis Therapeutics opens office and research facility in Shanghai China, laying the foundation for its next milestone. [...]
Axcynsis Therapeutics awarded TOP 5 Biotech Startups in Singapore 2022
Dec 27, 2022 – Axcynsis Therapeutics has been awarded “TOP 5 Biotech Startups in Singapore 2022” by Startup City APAC Magazine. Startup City is [...]
Axcynsis Therapeutics selected as 2022 TOP 50 Health Tech Startups in Southeast Asia
Listed as part of the 2022 Southeast Asia Health Tech 50 Nov 7, 2022 – Axcynsis Therapeutics has been selected to be part of [...]
Official opening of Axcynsis Therapeutics’ office and research facility in Singapore
Sep 1, 2022 – Singapore-based biotech start-up, Axcynsis Therapeutics, achieves its important milestone three months after its fund-raising announcement. Located at Singapore’s biotech hub, [...]
Tetris Therapeutics Announces Name Change to Axcynsis Therapeutics
July 20, 2022 – Singapore-based biotech start-up, Tetris Therapeutics Pte. Ltd. announced today that it has changed its name to Axcynsis Therapeutics Pte. Ltd.. [...]
Tetris Therapeutics raises US$15 million in seed funding to revolutionize targeted cancer treatments
One of the largest seed funds raised by a Singapore-based biotechnology company Tetris Therapeutics is an antibody drug conjugate (ADC) technology company May [...]